• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Catalyst Pharm Inc (NQ: CPRX )

    21.35 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 27
    Open 21.35
    Bid (Size) 21.27 (1)
    Ask (Size) 21.47 (1)
    Prev. Close 21.35
    Today's Range 21.35 - 21.35
    52wk Range 11.55 - 21.36
    Shares Outstanding 102,780,151
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
    CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
    Via Chartmill
    NASDAQ:CPRX is showing good growth, while it is not too expensive.
    CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is not too expensive for the growth it is showing. 
    Via Chartmill

    Performance

    YTD
    +24.78%
    +24.78%
    1 Month
    +3.19%
    +3.19%
    3 Month
    +40.65%
    +40.65%
    6 Month
    +28.46%
    +28.46%
    1 Year
    +75.29%
    +75.29%

    More News

    Read More
    Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
    Via Investor's Business Daily
    Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
    Via Chartmill
    Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
    Via Investor's Business Daily
    Biohaven Stock Earns Relative Strength Rating Upgrade
    Via Investor's Business Daily
    The Latest Analyst Ratings For Catalyst Pharmaceuticals
    Via Benzinga
    A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
    Via Benzinga
    SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
    Via Investor's Business Daily
    Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents.
    Via Chartmill
    NASDAQ:CPRX stands out as a growth opportunity that won't break the bank.
    Via Chartmill
    Immunome Stock Sees RS Rating Jump To 91
    Via Investor's Business Daily
    Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    PTC Therapeutics Stock Earns RS Rating Upgrade To 83
    Via Investor's Business Daily
    Top 3 Health Care Stocks That May Crash In August
    Via Benzinga
    CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Top 3 Health Care Stocks You May Want To Dump This Quarter
    Via Benzinga
    Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
    Via Investor's Business Daily
    Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Trading SMID Biotech Stocks In A Volatile Market
    Via Talk Markets
    Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.